Skip to main content

Table 1 Study patients’ characteristics

From: Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia

  all AML
n = 683
LOX-low group
n = 411, 60%
LOX-high group
n = 272, 40%
p-value
age at diagnosis
median (range)
46 (16–60) 47 (16–60) 50 (18–60) 0.045
Gender, Female, no. (percent) 364 (53) 226 (55) 138 (51) 0.276
Bone marrow blasts at diagnosis
[percent] median (range)
60.5 (3–100) 63.25 (8–100) 54.25 (3–96) < 0.001
WBC count at diagnosis
[Gpt/L] median (range)
14.5 (0.3–353) 26.1 (0.3–353) 6.5 (0.6–243.4) < 0.001
Platelet count at diagnosis
[Gpt/L] median (range)
52 (4–1308) 51 (4–1308) 52 (4–793) 0.626
Serum LDH at diagnosis
[U/l] median (range)
492 (100–7369) 527 (144–5934) 389 (100–7369) < 0.001
FLT3-ITD mutational status positive, no. (percent)a 167 (25) 122 (30) 45 (17) < 0.001
NPM1 mutational status positive, no. (percent)b 226 (33) 155 (38) 71 (26) 0.002
Combined NPM1/FLT3 status, no. (percent)
NPM1 wt/FLT3 wt 377 (56) 204 (50) 173 (65) < 0.001
NPM1 wt/FLT3 mut 70 (10) 46 (11) 24 (9)
NPM1 mut/FLT3 wt 130 (19) 80 (20) 50 (19)
NPM1 mut/FLT3 mut 96 (14) 75 (18) 21 (8)
Disease status at diagnosis, no. (percent)
 De novo AML 603 (88) 378 (92) 225 (83) 0.001
 t-AML 35 (5) 17 (4) 18 (7)
 mdsAML 45 (7) 16 (4) 29 (11)
FAB subtypes at diagnosis, no. (percent)
 M0 27 (4) 11 (3) 16 (6) 0.001
 M1 134 (20) 96 (23) 38 (14)
 M2 204 (30) 119 (29) 85 (31)
 M4 88 (13) 62 (15) 26 (10)
 M4eo 36 (5) 28 (7) 8 (3)
 M5a 71 (10) 35 (8) 36 (13)
 M5b 22 (3) 11 (3) 11 (4)
 M5 other 7 (1) 4 (1) 4 (1)
 M6 23 (3) 9 (2) 14 (5)
 M7 6 (1) 3 (1) 3 (1)
 RAEB 19 (3) 9 (2) 10 (4)
 RAEB-T 33 (5) 17 (4) 16 (6)
Cytogenetic subgroups, no. (percent)
 adverse risk 157 (23) 65 (16) 92 (34) < 0.001
 intermediate risk 444 (65) 287 (70) 157 (58)
 favorable risk 82 (12) 59 (14) 23 (8)
Common cytogenetic aberrations, no. (percent)
 Complex karyotype 90 (13) 42 (10) 48 (18) 0.005
 Normal karyotype 347 (49) 242 (59) 95 (35) < 0.001
 t(8;21) 39 (6) 26 (6) 13 (5) 0.394
 inv16 43 (6) 33 (8) 10 (4) 0.022
 monosomy 5 7 (1) 3 (1) 4 (1) 0.347
 del5q 48 (7) 20 (5) 28 (10) 0.007
 monosomy 7 30 (4) 14 (3) 16 (6) 0.122
 del7q 20 (3) 9 (2) 11 (4) 0.159
 monosomy other than chromosomes 5 or 7 43 (6) 17 (4) 26 (10) 0.004
 trisomy 8 74 (11) 31 (7) 43 (16) 0.001
 t(9;11) 17 (2) 4 (1) 13 (5) 0.002
 abnl(11q23) 59 (9) 22 (5) 37 (14) < 0.001
Extramedullary manifestation of AML, no. (percent) 59 (9) 28 (7) 31 (11) 0.037
  1. Table 1 The study patients’ characteristics at diagnosis are listed
  2. Abbreviations: AML acute myeloid leukemia, FAB French American British classification of acute leukemia, FLT3-ITD, FMS-like tyrosine kinase 3 internal tandem duplication, LDH lactate dehydrogenase, MDS myelodysplastic syndrome, mut mutated, NPM1 Nucleophosmin 1, RAEB refractory anemia with excess blasts, t-AML therapy-related AML, mdsAML AML with preceding MDS, WBC white blood count, wt wildtype
  3. aFLT3 mutation screening was performed in n = 678 patients at initial diagnosis
  4. bNPM1 mutation screening was performed in n = 674 patients at initial diagnosis